Yuan JJ, Lu Y, Cao JJ, Pei RZ, Gao RL. Hematopoiesis reconstitution and anti-tumor effectiveness of Pai-Neng-Da capsule in acute leukemia patients with haploidentical hematopoietic stem cell transplantation. World J Clin Cases 2022; 10(14): 4425-4435 [PMID: 35663068 DOI: 10.12998/wjcc.v10.i14.4425]
Corresponding Author of This Article
Rui-Lan Gao, PhD, Professor, Institute of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Hang Zhou 310006, Zhejiang Province, China. gaorl2021@163.com
Research Domain of This Article
Integrative & Complementary Medicine
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 16, 2022; 10(14): 4425-4435 Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4425
Hematopoiesis reconstitution and anti-tumor effectiveness of Pai-Neng-Da capsule in acute leukemia patients with haploidentical hematopoietic stem cell transplantation
Jiao-Jiao Yuan, Ying Lu, Jun-Jie Cao, Ren-Zhi Pei, Department of Hematology, The Affiliated People’s Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China
Rui-Lan Gao, Institute of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hang Zhou 310006, Zhejiang Province, China
Author contributions: Yuan JJ wrote the first draft of the manuscript; Lu Y critically reviewed and revised the manuscript; Cao JJ and Pei RZ collected and analyzed the clinical data; Gao RL designed the study and confirmed the statistical methods for the research; all the authors read and approved the final manuscript.
Supported byThe Zhejiang Provincial Science and Technology Program of Traditional Chinese Medicine, No. 2017ZA129 and No. 2018ZA112.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Affiliated People’s Hospital of Ningbo University Institutional Review Board (Approval No.2017022).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui-Lan Gao, PhD, Professor, Institute of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Hang Zhou 310006, Zhejiang Province, China. gaorl2021@163.com
Received: August 19, 2021 Peer-review started: August 19, 2021 First decision: November 11, 2021 Revised: March 25, 2022 Article in press: March 25, 2022 Published online: May 16, 2022
ARTICLE HIGHLIGHTS
Research background
New Chinese patent medicine Pai-Neng-Da (PND) Capsule exerts dual effect in promoting hematopoiesis recovery and regulating immunity. However, the application of PND capsule in haplo-HSCT has not yet been reported. To the best of our knowledge, this is the first study that evaluates the efficacy of PND capsule in the treatment of acute leukemia (AL) patients following haplo-HSCT.
Research motivation
The main problem in this study is whether PND capsule could promote hematopoiesis reconstitution following haplo-HSCT and whether it is related to the prognosis of AL patients with haplo-HSCT.
Research objectives
Objective to evaluate the role of PND capsule in AL patients with haplo-HSCT.
Research methods
We compared the therapeutic efficacy and the survival of AL patients with or without PND capsule during haplo-HSCT, using the chi-square test, Fisher’s exact test, and the Kaplan–Meier method.
Research results
PND capsule marginally reduced the rate of PGF and relapse. The 3-year relapse-free survival and progression-free survival were improved in the PND group than in the non-PND group. Also, the therapeutic efficacy of the PND group according to Chinese medical symptom scores was significantly better than that of the non-PND group.
Research conclusions
PND capsule could promote hematopoiesis reconstitution, improve the therapeutic efficacy of Chinese medical symptom scores, present anti-tumor effectiveness, and prolong the survival of AL patients with haplo-HSCT.
Research perspectives
The pathogenesis of primary PGF following haplo-HSCT is yet unclear. The effective therapies for primary PGF need to be explored.
